| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.098 | 0.04 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.04 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.081 | 0.04 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.098 | 0.04 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.04 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.04 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.096 | 0.05 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |